Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Author： Macaulay V. M.   Middleton M. R.   Protheroe A. S.   Tolcher A.   Dieras V.   Sessa C.   Bahleda R.   Blay J.-Y.   LoRusso P.   Mery-Mignard D.   Soria J.-C.  

Publisher： Oxford University Press

ISSN： 0923-7534

Source： Annals of Oncology, Vol.24, Iss.3, 2013-03, pp. : 784-791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

By Chiorean E.   Sweeney Christopher   Youssoufian Hagop   Qin Amy   Dontabhaktuni Aruna   Loizos Nick   Nippgen Johannes   Amato Robert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 595-604

Springer Publishing Company

Access to resources Recommend Favorite

In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

By            

Oncology Reports, Vol. 31, Iss. 1, 2014-01 ,pp. : 87-94

Spandidos Publications

Access to resources Recommend Favorite

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

By Mahadevan Daruka   Sutton Gregory   Arteta-Bulos Rafael   Bowden Chris   Miller Paul   Swart Rachel   Walker Mark   Haluska Paul   Munster Pamela   Marshall John   Hamid Omid   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 467-473

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

By Ekman Simon   Fröödin Jan-Erik   Harmenberg Johan   Bergman Antonina   Hedlund ÅÅsa   Dahg Pia   Alvfors Carina   Stååhl Birgitta   Bergströöm Stefan   Bergqvist Michael  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas

By Wu Pei-Fang   Huang Wen-Chang   Yang James   Lu Yen-Shen   Shih Jin-Yuan   Wu Shang-Gin   Lin Ching-Hung   Cheng Ann-Lii  

Journal of Neuro-Oncology, Vol. 115, Iss. 1, 2013-10 ,pp. : 61-70

Springer Publishing Company

Access to resources Recommend Favorite